Tacrolimus eye drops for non-infectious anterior uveitis
Part of Eyes & vision clinical trials.
This trial tests a new eye drop (tacrolimus) to treat non-infectious anterior uveitis, an inflammation in the front part of the eye. It may help reduce the need for steroid eye drops.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have active non-infectious anterior uveitis (inflammation in the front part of your eye that is not caused by an infection)
- Your doctor says you need to start or increase steroid eye drops to control the inflammation
- Your eye symptoms started within the last 4 weeks
- You do not have other eye problems or infections that might interfere with the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests the safety and side effects of ASP7317 in older adults whose central vision is worsening from dry age-related macular degeneration (geographic atrophy). If you qualify, you would receive treatment in the study eye and be closely monitored for about a year.
This trial tests whether tacrolimus eye drops can reduce the symptoms of vernal keratoconjunctivitis (a severe eye allergy) in children aged 5 to 15. If effective, the treatment could provide a new option to control this uncomfortable condition.
This trial tests a new drug called FXS5626 to treat non-infectious uveitis—inflammation inside the eye that doesn't come from infection. The study looks at whether this drug can reduce eye inflammation and improve vision in people whose condition isn't controlled with steroid eye drops and oral steroids alone.
This trial tests a new drug called tulisokibart for people with active inflammation in the back of the eye (uveitis). The drug may help reduce inflammation and prevent vision loss.
This study tests a combination of two medicines, mycophenolate mofetil and adalimumab, to help control eye inflammation (uveitis) and reduce the need for steroids. It is for people who still have active inflammation despite taking a steroid medication like prednisone.
This trial tests if adding cyclosporine A to the standard natamycin eye drops can better treat fungal eye infections. It may help people with moderate vision loss from a fungal corneal infection.
Hear when a new Non-infectious Anterior Uveitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.